ADVM - Adverum Biotechnologies Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript
2024-07-17 15:35:06 ET
Adverum Biotechnologies, Inc. (ADVM)
26-Week Interim Analysis of the LUNA Phase 2 Trial Update Call
July 17, 2024 08:00 AM ET
Company Participants
Mike Zanoni - Head of IR
Laurent Fischer - President & CEO
Charles Wykoff - Director of Research, Retina Consultants of Texas
Conference Call Participants
Joon Lee - Truist Securities
Joseph Thome - TD Cowen
Francois Brisebois - Oppenheimer
Graig Suvannavejh - Mizuho Securities
Luca Issi - RBC Capital
Daniil Gataulin - Chardan
Presentation
Operator
Hello, ladies and gentlemen. Thank you for standing by, and welcome to the Adverum's Webcast to discuss the 26-Week Interim Analysis of the ongoing LUNA Phase 2 trial that was presented earlier today at the 2024 ASRS Annual Meeting. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, today's call is being recorded.
It is now my pleasure to turn the floor over to Mike Zanoni, Adverum's Head of Investor Relations, who will make introductory comments.
Mike Zanoni
Thank you, operator. Good morning, and welcome, everyone. Adverum recently issued a press release providing the details of the company's 26-week interim analysis of the ongoing LUNA Phase 2 trial. The press release is available in the Investor Relations section of the company's website at investors adverum.com.
Today's call will be led by Dr. Laurent Fischer, President and Chief Executive Officer. He'll be joined by Dr. Star Seyedkazemi, Chief Development Officer; Peter Soparkar, Chief Operating Officer; and Linda Rubinstein, Chief Financial Officer. In addition, it is our pleasure to welcome Dr. Charles Wykoff, Director of Research, and the Retina Consultants of Texas and Professor Clinical Ophthalmology at the Blanton Eye Institute of Houston Methodist Hospital. Dr. Wykoff is a principal investigator on the LUNA clinical study has more than five years of hand-on clinical experience with Ixo-vec.
As a reminder, we may be making forward-looking statements, including statements related to the potential of Ixo-vec and plans and milestones regarding Ixo-vec, which are based on certain assumptions made by Adverum based on current conditions and expected future developments. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements, as a result of various risks and uncertainties, which are described under the caption of Risk Factors in Adverum's filings with the Securities and Experience Commission. For further details, please visit our website.
At this time, it is my pleasure to turn the call over to Adverum's President and Chief Executive Officer; Dr. Laurent Fischer. Laurent?
Laurent Fischer
Thank you, Mike, and thank you, everyone for joining us today to discuss these very exciting results of the LUNA 26-week interim analysis with our pioneering intravitreal gene therapy product candidate, Ixo-vec. It is my pleasure to welcome an esteemed retina specialist to the call, Dr. Charles Wykoff. Earlier today, Dr. Wykoff presented the LUNA 26-week interim analysis at the ASRS Annual Meeting currently held in Stockholm, Sweden.
To kick things off, I would like to remind you of the goals of the LUNA study, which were to select the dose and [indiscernible] regimen to enable pivotal Phase III trials, which we plan to initiate in the first half of next year....
Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript